Lumirix® Efficacy in Chinese patients
This image is for illustrative purposes only.
Ruxolitinib’s efficacy in Chinese patients
The study enrolled patients with longstanding vitiligo, with 42% having progressive disease and 94% having received prior therapy4
Ruxolitinib cream achieved F-VASI75 responses in 50% of patients at Week 24,4 and 80% of patients were satisfied with the improvement14
a F-PaGIC-V, facial Patient’s Global Impression of Change-Vitiligo, is a 7-point scale, with “very much improved” or “much improved”.14
BID: twice a day; BSA: Body surface area; F-PaGIC-V, Facial Patient’s Global Impression of Change–Vitiligo; F-VASI: Facial Vitiligo Area Scoring Index; T-BSA: total body surface area.
References
4. Huang H, et al. Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo. J Am Acad Dermatol 2025;93(2):475–477.
14. Huang H, et al. Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo. J Am Acad Dermatol 2025;93(2):475–477 supplementary appendix.
